

Supplementary Materials for Financial Statements For the second quarter Ended September 30, 2022 (April 1, 2022 to September 30, 2022)

November 11, 2022

Yakult Honsha Co., Ltd. Public Relations Department Investor Relations Department URL https://www.yakult.co.jp/company/ir/

Contents

Consolidated

The annual forecast for the fisical year ending March 31, 2023 has been revised for both Consolidated and Non - Consolidated.

1. Major Increases (Decreases) in Consolidated Balance Sheet	•••	1
2. Major Increases (Decreases) in Consolidated Statement of Income	•••	2
3. Performance Overview	•••	3 - 4
4. Segment Information	•••	5 - 13
5. Overview of Overseas Companies	•••	14 - 15

Non - Consolidated

1.	Major Increases (Decreases) in Non-consolidated Balance Sheet	•••	16
2.	Major Increases (Decreases) in Non-consolidated Statement of Income	•••	17
3.	Performance Overview	•••	18
4.	Breakdown of Sales	•••	19 - 21
5.	Breakdown of Selling, General and Administrative Expenses	•••	21
6.	Retirement benefit expneses	•••	21
7.	Head Office Employees	•••	22
8.	Yakult Sales Company	•••	22
9.	Sales Personnel by Department	•••	22
10.	Average figure of Yakult Lady	•••	22

Reference

•••	26 - 27
•••	25
•••	24
•••	23
	•••• ••• •••

About a numeric display of this material

1. Unit of money : Less than one million yen is rounded down.

2. Quantity results: Less than 1000 is rounded off.

3.Year on year percentage: The second place is rounded off after the decimal point.

Consolidated

1. Major Increases (Decreases) in Consolidated Balance Sheet

(Millions of								
	As of Mar. 31	As of Sep. 30	Increase	Primary reason for change				
	2022	2022	(Decrease)					
Total Assets	672,855	745,449	72,594					
Current assets				Increase in overseas subsidiaries				
Cash and deposits	202,941	223,557	20,615	(FX impact)				
Notes and accounts receivable - trade	52,581	65,423	12,842					
Inventories	30,649	36,978	6,328					
Others	14,226	17,860	3,634					
Non-current assets								
Property, plant and equipment								
Buildings and structures (net)	84,139	87,214	3,075					
Others (net)	127,017	140,505	13,488					
Intangible assets	5,386	5,675	288					
Investments and other assets								
Investment securities	67,628	69,429	1,800					
Shares of affiliates	73,044	82,013	8,969					
Others	15,240	16,791	1,550					
Total Liabilities	187,920	202,571	14,650					
Current liabilities								
Notes and accounts payable - trade	26,039	31,371	5,331					
Short-term loans payable	10,239	11,082	842					
Others	53,001	59,553	6,552					
Non-current liabilities								
Long-term loans payable	60,298	57,716	(2,582)					
Net defined benefit liability	4,280	4,319	38					
Others	34,059	38,527	4,467					
Total Net Assets	484,935	542,878	57,943					
Shareholders' equity	454,169	457,474	3,305					
Accumulated other comprehensive income	(8,101)	37,009	45,110	Increase in Foreign currency translation adjustment				
Non-controlling interests	38,867	48,394	9,527					

2. Major Increases (Decreases	2Q of FY 2021	Increase (De			of yen. %) Revised *	
	(2021.4~9)	(2022.4~9)	Amount	Retio	Primary reason for change	Forecasts (2022.4~9
Net sales	202,996	232,785	29,788	14.7		228,000
(Net sales by business segments)	,					
Food and beverages (Japan)	101,355	117,322	15,966	15.8	Increase in Dairy products	
Food and beverages (Overseas)	88,847	101,806	12,958	14.6	FX impact +12,415	
Pharmaceuticals	8,618	7,233	(1,384)	(16.1)	_	
Others	9,243	12,242	2,998	32.4		
Adjustments	(5,068)	(5,819)	(750)	14.8		
Cost of sales	80,398	91,479	11,080	13.8		
Gross profit	122,597	141,306	18,708	15.3		
Gross profit margin	60.4	60.7	0.3			
Selling, general and administrative expenses	94,775	106,009	11,234	11.9		
Selling expenses	43,647	48,123	4,475			
General and administrative expenses	51,127	57,886	6,758			
Operating profit	27,822	35,296	7,473	26.9		29,000
Operating profit margin	13.7	15.2	1.5			
(Operating profit by business segments)						
Food and beverages (Japan)	14,938	24,897	9,959	66.7		
Food and beverages (Overseas)	19,414	17,510	(1,903)	(9.8)	FX impact +2,232	
Pharmaceuticals	1,328	727	(600)	(45.2)		
Others	(119)	1,141	1,261	_		
Adjustments	(7,738)	(8,981)	(1,242)	16.1		
{ include corporate expenses }	{ (4,878) }	{ (5,392) }	{ (513) }	10.5		
Non-operating incomes	8,554	7,402	(1,151)	(13.5)		
Interest income	1,526	2,346	819			
Dividend income	1,052	1,057	5			
Share of profit of entities accounted for using equity method	4,083	2,113	(1,970)			
Others	1,890	1,885	(5)			
Non-operating expenses	635	731	95	15.0		
Interest expenses	352	337	(14)			
Others	283	393	110			
Ordinary profit	35,741	41,968	6,227	17.4	FX impact +2,616	36,500
Ratio of ordinary profit to net sales	17.6	18.0	0.4			
Extraordinary income	2,425	480	(1,944)	(80.2)		
Extraordinary losses	1,033	172	(861)	(83.3)		
Profit before income taxes	37,132	42,276	5,143	13.9		
Income taxes	9,434	12,945	3,510			
Profit	27,698	29,331	1,633	5.9		1
Profit attributable to non-controlling interests	2,122	2,413	291	13.7		1
Profit attributable to owners of parent	25,576	26,918	1,341	5.2	FX impact +1,845	24,000
Ratio of profit attributable to owners of parent to net sales	12.6	11.6	(1.0)			

Major Increa araasas) in Consolidated Statement of I (D 2

* The forecast for 2nd quarter of FY2022 announced on July 29, 2022.

Performance Overview 3.

(1) Breakdown of	Statement of	f Income				(Millions	of yen. %)		
	Fisca	ıl year ended	March 31, 20)22	Fiscal year ending March 31, 2023				
	Result of 2nd quarter	Year on vear	Annual results	Year on vear	Result of 2nd quarter	Year on vear	Annual forecasts	Year on year	
				2		2		ž	
Net sales	202,996	106.6	415,116	107.6	232,785	114.7	481,000	115.9	
Operating profit	27,822	115.1	53,202	121.8	35,296	126.9	64,000	120.3	
Ordinary profit	35,741	106.7	68,549	119.0	41,968	117.4	79,000	115.2	
Profit attributable to owners of parent	25,576	117.8	44,917	114.4	26,918	105.2	50,000	111.3	

(1) Breakdown of Statement of Income

(2) Ratios of Consolidated to Non-consolidated Results

(Times)

	Fiscal year ended	l March 31, 2022	Fiscal year ending March 31, 2023			
	Result of 2nd quarter	Annual results	Result of 2nd quarter	Annual forecasts		
Net sales	2.58	2.65	2.64	2.75		
Operating profit	4.26	4.10	2.53	2.91		
Ordinary profit	3.04	1.88	1.96	1.63		
Profit attributable to owners of parent	2.51	1.44	1.55	1.28		

(3) Share of profit of entities accounted for using equity method

(Millions of yen. %)

	Fisca	l year ended	March 31, 20	022	Fiscal year ending March 31, 2023			
	Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year
Share of profit of entities accounted for using equity method	4,083	199.1	6,432	164.5	2,113	51.8	4,500	70.0

(4) Major Items in selling, general and administrative expenses

(Millions of yen. %)

	Fisca	l year ended	March 31, 20	022	Fiscal year ending March 31, 2023			
	Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year
Advertising expenses	7,815	108.6	17,459	101.9	7,907	101.2	—	_
Promotion expenses	3,323	90.0	7,085	98.0	3,716	111.8	_	_
Sales commission	13,924	113.9	28,357	111.3	15,042	108.0	_	
Freightage expenses	6,492	90.5	13,378	91.3	7,561	116.5	—	_
Salaries and allowance	23,057	107.6	47,354	109.4	26,811	116.3	_	—
Depreciation	2,328	105.0	4,563	100.9	2,297	98.7	_	
Research and development expenses	4,281	105.7	8,617	102.0	4,367	102.0	_	

(5) Capital investments, Depreciation, Research and development expenses (Millions of yen. %)										
	Fisca	al year ended	March 31, 2	022	Fiscal year ending March 31, 2023					
	Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on		
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year		
Capital investments	11,785	117.1	26,092	110.4	14,344	121.7	40,000	153.3		
Depreciation	11,560	107.3	23,769	107.5	12,163	105.2	25,500	107.3		
Research and development expenses	4,299	105.6	8,655	102.0	4,388	102.1	9,417	108.8		

(5) Capital investments, Depreciation, Research and development expenses

Breakdown of investment

	Fiscal year ended Marc	h 31, 2	2022	Forecast of full fiscal year ending March 31, 2023		
	Investment in Parent company	5.6	billion yen	Investment in Parent company	14.0	billion yen
Capital investments	Investment in Plants(subsidiaries)	2.1	billion yen	Investment in Plants(subsidiaries)	5.0	billion yen
	Investment in Overseas subsidiaries	16.5	billion yen	Investment in Overseas subsidiaries	20.2	billion yen
Research and	Food and beverages	6.8	billion yen	Food and beverages	7.7	billion yen
development	Pharmaceuticals	1.1 billion yen		Pharmaceuticals	0.9	billion yen
	Others	0.6	billion yen	Others	0.7	billion yen

\langle Reference \rangle Consolidated Statements of Cash Flows Overview

			(Millions of yen)
	2Q of FY 2021 (2021.4 ~ 2021.9)	2Q of FY 2022 (2022.4 ~ 2022.9)	Increase (Decrease) Amount
Cash flows from operating activities	30,378	32,369	1,991
Cash flows from investing activities	(3,517)	(7,940)	(4,422)
Cash flows from financing activities	(21,671)	(28,063)	(6,391)
Effect of exchange rate change on cash and cash equivalents	7,546	21,186	13,639
Net increase (decrease) in cash and cash equivalents	12,735	17,552	4,816
Cash and cash equivalents at beginning of period	122,766	150,725	27,959
Cash and cash equivalents at end of period	135,502	168,278	32,775

4. Segment Information

(1) Result of the second quarter

① Results of the second quarter ended September 30, 2021 (April 1, 2021 ~ September 30, 2021)

	-	•			Millions of yen. %)
			Food and beverages		
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe
Net sales	101,355	88,847	22,842	61,171	4,834
Percentage of net sales	49.9	43.8	11.3	30.1	2.4
Year on year	97.0	108.7	107.1	108.9	113.3
Operating expenses	86,417	69,433	16,668	48,644	4,121
Year on year	93.8	113.4	106.3	115.9	114.6
Operating profit (loss)	14,938	19,414	6,174	12,527	712
Year on year	120.8	94.7	109.5	88.3	106.5
Operating profit margin	14.7	21.9	27.0	20.5	14.7
	Pharmaceuticals	Others	Total	Adjustments	Consolidated
Net sales	8,618	9,243	208,065	(5,068)	202,996
Percentage of net sales	4.2	4.6	102.5	(2.5)	100.0
Year on year	96.6	118.4	102.5	40.4	106.6
Operating expenses	7,289	9,362	172,503	2,669	175,173
Year on year	87.6	117.0	101.7		105.4
Operating profit (loss)	1,328	(119)	35,561	(7,738)*	27,822
Year on year	221.3		106.9	85.0	115.1
Operating profit margin	15.4	(1.3)			13.7

* The details of "Adjustments" are as follows.

· Administrative expenses in parent company : 4,878 million yen

• Elimination of royalty income : 2,860 million yen

			Food and beverages	•	winnons of yen. %
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe
Net sales	117,322	101,806	30,344	66,429	5,032
Percentage of net sales	50.4	43.7	13.0	28.5	2.2
Year on year	115.8	114.6	132.8	108.6	104.1
Operating expenses	92,424	84,295	22,316	57,171	4,807
Year on year	107.0	121.4	133.9	117.5	116.6
Operating profit (loss)	24,897	17,510	8,028	9,258	224
Year on year	166.7	90.2	130.0	73.9	31.5
Operating profit margin	21.2	17.2	26.5	13.9	4.5
	Pharmaceuticals	Others	Total	Adjustments	Consolidated
Net sales	7,233	12,242	238,604	(5,819)	232,785
Percentage of net sales	3.1	5.3	102.5	(2.5)	100.0
Year on year	83.9	132.4	114.7	114.8	114.7
Operating expenses	6,506	11,100	194,327	3,161	197,488
Year on year	89.2	118.6	112.7	118.4	112.7

(2) Results of the second quarter ended September 30, 2022 (April 1, $2022 \sim$ September 30, 2022)

(Millions of yen. %)

(8,981)*

116.1

35,296

126.9

15.2

* The details of "Adjustments" are as follows.

Year on year

Operating profit

(loss)

margin

Operating profit

· Administrative expenses in parent company : 5,392 million yen

727

54.8

10.1

• Elimination of royalty income : 3,588 million yen

1,141

9.3

44,277

124.5

\langle Reference \rangle

Result of the second quarter ended September 30, 2022 (April 1, $2022 \sim$ September 30, 2022) (on the basis of average exchange rate between Jan. 2021 and Jun. 2021)

					Millions of yen. %
			Food and beverages		
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe
Net sales	117,322	89,390	26,018	58,555	4,816
Percentage of net sales	53.2	40.6	11.8	26.6	2.2
Year on year	115.8	100.6	113.9	95.7	99.6
Operating expenses	92,424	74,112	19,080	50,405	4,626
Year on year	107.0	106.7	114.5	103.6	112.3
Operating profit (loss)	24,897	15,278	6,938	8,150	189
Year on year	166.7	78.7	112.4	65.1	26.7
Operating profit margin	21.2	17.1	26.7	13.9	3.9
	Pharmaceuticals	Others	Total	Adjustments	Consolidated
Net sales	7,233	12,242	226,189	(5,819)	220,369
Percentage of net sales	3.3	5.5	102.6	(2.6)	100.0
Year on year	83.9	132.4	108.7	114.8	108.6
Operating expenses	6,506	11,100	184,143	3,161	187,305
Year on year	89.2	118.6	106.7	118.4	106.9
Operating profit (loss)	727	1,141	42,045	(8,981)*	33,064
Year on year	54.8		118.2	116.1	118.8
Operating profit margin	10.1	9.3			15.0

* The details of "Adjustments" are as follows.

• Administrative expenses in parent company : 5,392 million yen

• Elimination of royalty income : 3,588 million yen

(2) Quarterly Results

① Quarterly Results of the Second quater ended March 31, 2022 (July 1, 2021 ~ September 30, 2021)*

(Millior	ns of y	ven. %)

			Food and beverages		
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe
Net sales	50,712	49,264	11,966	34,925	2,372
Percentage of net sales	47.6	46.2	11.2	32.8	2.2
Year on year	95.6	116.9	122.4	115.1	116.6
Operating expenses	42,683	37,730	8,738	26,989	2,003
Year on year	91.5	121.4	124.1	120.5	122.0
Operating profit (loss)	8,029	11,533	3,228	7,936	369
Year on year	126.2	104.2	118.0	99.9	94.2
Operating profit margin	15.8	23.4	27.0	22.7	15.6
	Pharmaceuticals	Others	Total	Adjustments	Consolidated
Net sales	4,282	4,731	108,991	(2,417)	106,573
Percentage of net sales	4.0	4.5	102.3	(2.3)	100.0

129.0

5,008

127.0

(276)

(5.8)

105.5

88,980

103.7

20,010

114.1

44.5

1,384

(3,801)

86.1

108.9

90,364

106.6

16,208

123.6

15.2

* The above results are the amount obtained by subtracting the result for the 1st quarter (on the basis of

average exchange rate between Jan. 2021 and Mar. 2021) from the cumulative results for the 2nd quarter

(on the basis of average exchange rate between Jan. 2021 and Jun. 2021).

95.5

3,557

86.6

724

192.4

16.9

** The details of "Adjustments" are as follows.

Year on year

Year on year

Year on year

Operating profit

(loss)

margin

Operating profit

Operating expenses

- · Administrative expenses in parent company : 2,330 million yen
- Elimination of royalty income : 1,471 million yen

			F 1		Aillions of yen. %	
		Food and beverages				
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe	
Net sales	61,510	56,070	16,466	37,146	2,457	
Percentage of net sales	49.3	44.9	13.2	29.7	2.0	
Year on year	121.3	113.8	137.6	106.4	103.6	
Operating expenses	47,097	46,232	12,216	31,684	2,331	
Year on year	110.3	122.5	139.8	117.4	116.4	
Operating profit (loss)	14,412	9,838	4,249	5,462	126	
Year on year	179.5	85.3	131.6	68.8	34.2	
Operating profit margin	23.4	17.5	25.8	14.7	5.1	
	Pharmaceuticals	Others	Total	Adjustments	Consolidated	
Net sales	3,378	6,590	127,548	(2,746)	124,801	
Percentage of net sales	2.7	5.3	102.2	(2.2)	100.0	
Year on year	78.9	139.3	117.0	113.6	117.1	
Year on year Operating expenses	78.9 3,221	139.3 6,054	117.0 102,605	113.6 1,670	117.1 104,275	
-						
Operating expenses	3,221	6,054	102,605	1,670	104,275	
Operating expenses Year on year Operating profit	3,221 90.5	6,054 120.9	102,605 115.3	1,670 120.7	104,275 115.4	

2 Quarterly results of the second quarter ending March 31, 2023 (July 1, 2022 ~ September 30, 2022) *

* The above results are the amount obtained by subtracting the result for the 1st quarter (on the basis of

average exchange rate between Jan. 2022 and Mar. 2022) from the cumulative results for the 2nd quarter

(on the basis of average exchange rate between Jan. 2022 and Jun. 2022).

** The details of "Adjustments" are as follows.

- Administrative expenses in parent company : 2,592 million yen
- · Elimination of royalty income : 1,824 million yen

\langle Reference \rangle

Quarterly results of the second quarter ending March 31, 2023 (July 1, 2022 ~ September 30, 2022)^{*}

					Millions of yen. %	
		Food and beverages				
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe	
Net sales	61,510	48,191	13,714	32,143	2,333	
Percentage of net sales	52.6	41.2	11.7	27.5	2.0	
Year on year	121.3	97.8	114.6	92.0	98.4	
Operating expenses	47,097	39,838	10,168	27,448	2,220	
Year on year	110.3	105.6	116.4	101.7	110.9	
Operating profit (loss)	14,412	8,353	3,546	4,694	112	
Year on year	179.5	72.4	109.8	59.2	30.5	
Operating profit margin	23.4	17.3	25.9	14.6	4.8	
	Pharmaceuticals	Others	Total	Adjustments	Consolidated	
Net sales	3,378	6,590	119,669	(2,746)	116,922	
Percentage of net sales	2.9	5.6	102.3	(2.3)	100.0	
Year on year	78.9	139.3	109.8	113.6	109.7	
Operating expenses	3,221	6,054	96,211	1,670	97,881	
Year on year	90.5	120.9	108.1	120.7	108.3	
Operating profit (loss)	156	535	23,457	(4,417)**	19,040	
Year on year	21.7		117.2	116.2	117.5	
Operating profit margin	4.6	8.1			16.3	

* The above results are the amount obtained by subtracting the result for the 1st quarter (on the basis of

average exchange rate between Jan. 2021 and Mar. 2021) from the cumulative results for the 2nd quarter

(on the basis of average exchange rate between Jan. 2021 and Jun. 2021).

** The details of "Adjustments" are as follows.

- · Administrative expenses in parent company : 2,592 million yen
- Elimination of royalty income : 1,824 million yen

(2) Annual financial forecast

1 Result of fiscal year ended March 31, 2022 (April 1, 2021 ~ March 31, 2022)

(Millions of yen. %)

	Food and beverages				
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe
Net sales	203,293	185,000	47,388	128,199	9,413
Percentage of net sales	49.0	44.5	11.4	30.9	2.2
Year on year	98.2	111.8	113.2	111.5	109.9
Operating expenses	175,049	147,014	34,833	103,390	8,790
Year on year	95.5	114.9	110.6	116.7	111.1
Operating profit (loss)	28,243	37,986	12,554	24,808	622
Year on year	118.8	101.5	120.8	94.0	96.0
Operating profit margin	13.9	20.5	26.5	19.4	6.6
	Pharmaceuticals	Others	Total	Adjustments	Consolidated
Net sales	Pharmaceuticals 16,992	Others 19,473	Total 424,760	Adjustments (9,644)	Consolidated 415,116
Net sales Percentage of net sales					
Percentage of net	16,992	19,473	424,760	(9,644)	415,116
Percentage of net sales	16,992 4.1	19,473 4.7	424,760 102.3	(9,644)	415,116 100.0
Percentage of net sales Year on year	16,992 4.1 93.8	19,473 4.7 110.0	424,760 102.3 104.0	(9,644) (2.3) 42.7	415,116 100.0 107.6
Percentage of net sales Year on year Operating expenses	16,992 4.1 93.8 14,358	19,473 4.7 110.0 20,218	424,760 102.3 104.0 356,641	(9,644) (2.3) 42.7	415,116 100.0 107.6 361,913
Percentage of net sales Year on year Operating expenses Year on year Operating profit	16,992 4.1 93.8 14,358 80.1	19,473 4.7 110.0 20,218 113.3	424,760 102.3 104.0 356,641 102.8	(9,644) (2.3) 42.7 5,272 	415,116 100.0 107.6 361,913 105.8

* The details of "Adjustments" are as follows.

• Administrative expenses in parent company : 9,446 million yen

• Elimination of royalty income : 5,470 million yen

			Food and beverages		winnons of yen. 70
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe
Net sales	237,900	216,900	63,900	142,500	10,500
Percentage of net sales	49.4	45.1	13.3	29.6	2.2
Year on year	117.0	117.2	134.8	111.2	111.5
Operating expenses	195,000	180,200	48,300	121,500	10,400
Year on year	111.4	122.6	138.7	117.5	118.3
Operating profit (loss)	42,900	36,700	15,600	21,000	100
Year on year	151.9	96.6	124.3	84.6	16.1
Operating profit margin	18.0	16.9	24.4	14.7	1.0
	Pharmaceuticals				
	rnannaceuticais	Others	Total	Adjustments	Consolidated
Net sales	13,000	25,300	Total 493,100	Adjustments (12,100)	Consolidated 481,000
Net sales Percentage of net sales				-	
Percentage of net	13,000	25,300	493,100	(12,100)	481,000
Percentage of net sales	13,000 2.7	25,300 5.3	493,100 102.5	(12,100) (2.5)	481,000 100.0
Percentage of net sales Year on year	13,000 2.7 76.5	25,300 5.3 129.9	493,100 102.5 116.1	(12,100) (2.5) 125.5	481,000 100.0 115.9
Percentage of net sales Year on year Operating expenses	13,000 2.7 76.5 12,800	25,300 5.3 129.9 23,800	493,100 102.5 116.1 411,800	(12,100) (2.5) 125.5 5,200	481,000 100.0 115.9 417,000
Percentage of net sales Year on year Operating expenses Year on year Operating profit	13,000 2.7 76.5 12,800 89.1	25,300 5.3 129.9 23,800 117.7	493,100 102.5 116.1 411,800 115.5	(12,100) (2.5) 125.5 5,200 98.6	481,000 100.0 115.9 417,000 115.2

2 Annual forecast for the fiscal year ending March 31, 2023 (April 1, 2022 ~ March 31, 2023)

(Millions of yen. %)

* The details of "Adjustments" are as follows.

· Administrative expenses in parent company : 10,700 million yen

• Elimination of royalty income : 6,600 million yen

\langle Reference \rangle

Annual forecast for the fiscal year ending March 31, 2023 (April 1, 2022 ~ March 31, 2023) (on the basis of average exchange rate between Jan. 2021 and Dec. 2021)

	(Millions	of ven.	%)
--	---	----------	---------	---	---

		1	Food and beverages	X	vinitions of yell. 70)
	Japan	Overseas Total	The Americas	Asia and Oceania	Europe
Net sales	237,900	188,900	53,600	125,300	10,000
Percentage of net sales	52.5	41.7	11.8	27.7	2.2
Year on year	117.0	102.1	113.1	97.7	106.2
Operating expenses	195,000	157,300	40,400	107,000	9,900
Year on year	111.4	107.0	116.0	103.5	112.6
Operating profit (loss)	42,900	31,600	13,200	18,300	100
Year on year	151.9	83.2	105.1	73.8	16.1
Operating profit margin	18.0	16.7	24.6	14.6	1.0
	Pharmaceuticals	Others	Total	Adjustments	Consolidated
					Consondated
Net sales	13,000	25,300	465,100	(12,100)	453,000
Net sales Percentage of net sales	13,000 2.9	25,300 5.6			
Percentage of net			465,100	(12,100)	453,000
Percentage of net sales	2.9	5.6	465,100 102.7	(12,100) (2.7)	453,000 100.0
Percentage of net sales Year on year	2.9 76.5	5.6 129.9	465,100 102.7 109.5	(12,100) (2.7) 125.5	453,000 100.0 109.1
Percentage of net sales Year on year Operating expenses	2.9 76.5 12,800	5.6 129.9 23,800	465,100 102.7 109.5 388,900	(12,100) (2.7) 125.5 5,200	453,000 100.0 109.1 394,100
Percentage of net sales Year on year Operating expenses Year on year Operating profit	2.9 76.5 12,800 89.1	5.6 129.9 23,800 117.7	465,100 102.7 109.5 388,900 109.0	(12,100) (2.7) 125.5 5,200 98.6	453,000 100.0 109.1 394,100 108.9

* The details of "Adjustments" are as follows.

• Administrative expenses in parent company : 10,700 million yen

• Elimination of royalty income : 6,600 million yen

Overview of Overseas Companies 5.

(1) Dairy Products sales (Bottles sold per day)

[Results from January to Ju	ne 2022]						(As of June	30, 2022)	
*	Consolidation	Sales quantity	Year on	Started	Consolidation	Currency	I	Exchange rat	e**	
Company Name [*]	Classification	(Thousands of bottles / day)	year (%)	Business	Classification (%)	Unit	Average Jan. ~ Sep. 2022	Average Jan. ~ Jun. 2022	Average Jan. ~ Jun. 2021	
Yakult Taiwan Co., Ltd.	Equity method	624	99.0	Mar. 1964	25.00	NT\$	4.4	4.33	3.89	
Hong Kong Yakult Co., Ltd.	Consolidated	330	78.5	Jun. 1969	80.00	HK\$	16.52	15.91	13.98	
Yakult (Thailand) Co., Ltd.	Equity method	2,244	103.7	Jun. 1971	25.29	В	3.41	3.38	3.39	
Korea Yakult (hy Co., Ltd.)	Equity method	2,471	90.9	Aug. 1971	38.30	W	0.1013	0.1006	0.0969	
Yakult Philippines, Inc.	Equity method	3,693	102.1	Oct. 1978	40.00	Р	2.40	2.38	2.24	
Yakult (Singapore) Pte. Ltd.	Consolidated	248	95.7	Jul. 1979	100.00	S\$	93.73	90.95	81.36	
PT. Yakult Indonesia Persada	Consolidated	7,328	103.0	Jan. 1991	100.00	Rp	0.0089	0.0086	0.0076	
Yakult Australia Pty. Ltd.	Consolidated	309	112.9	Feb. 1994	100.00	A\$	90.78	88.91	83.37	
Guangzhou Yakult Co., Ltd.	Consolidated	2,412	88.4	Jun. 2002	95.00	RMB	19.46	19.14	16.77	
Yakult (Malaysia) Sdn. Bhd.	Consolidated	386	116.3	Feb. 2004	100.00	MYR	29.62	29.02	26.39	
Shanghai Yakult Co., Ltd.	Consolidated	347	81.9	May 2005	100.00	RMB	19.46	19.14	16.77	
Beijing Yakult Co., Ltd.	Consolidated	333	90.9	Jun. 2006	100.00	RMB	19.46	19.14	16.77	
Yakult (China) Corporation	Consolidated	2,937	87.2	Apr. 2007	100.00	RMB	19.46	19.14	16.77	
Yakult Vietnam Co., Ltd.	Consolidated	863	119.9	Sep. 2007	80.00	VND	0.0056	0.0054	0.0047	
Yakult Danone India Pvt. Ltd.	Consolidated	227	101.5	Jan. 2008	50.00	INR	1.72	1.72	1.50	
Yakult Middle East FZCO	Consolidated	18	82.9	Mar. 2017	100.00	AED	35.25	33.91	29.54	
Yakult Myanmar Co., Ltd.	Consolidated	_	_	Aug. 2019	100.00	MMK	0.0701	0.0701	0.0727	
Asia and Oceania Tot	tal	24,773	97.6	Marketing Popu	lation: 1,544	,469 thousa	and people Pe	opulation rati	io: 1.60 %	
(Consolidated subsidiari	ies Total)	15,741	96.8							
Yakult S/A Ind. E Com. (Brazil)	Consolidated	1,431	98.6	Oct. 1968	51.42	R	25.37	24.81	20.17	
Yakult S.A. De C.V. (Mexico)	Consolidated	3,750	108.6	Oct. 1981	61.21	NP	6.41	6.16	5.35	
Yakult U.S.A. Inc.	Consolidated	626	119.5	Oct. 1999	100.00	US\$	129.48	124.54	108.47	
The Americas Total		5,808	107.0	Marketing Popu	lation: 539,2	235 thousa	nd people P	opulation rat	tio: 1.08 %	
Yakult Nederland B.V.	Consolidated	181	95.1	Apr. 1994	100.00	EUR	136.60	135.14	130.47	
Yakult Belgium N.V./S.A.	Consolidated	58	97.3	Apr. 1995	100.00	EUR	136.60	135.14	130.47	
Yakult Europe B.V.	Consolidated	27	95.6	Mar. 1996	100.00	EUR	136.60	135.14	130.47	
Yakult UK Ltd.	Consolidated	240	98.2	Apr. 1996	100.00	£	160.74	159.89	150.79	
Yakult Deutschland GmbH	Consolidated	80	99.3	Apr. 1996	100.00	EUR	136.60	135.14	130.47	
Yakult Oesterreich GmbH	Consolidated	11	88.1	Dec. 2005	100.00	EUR	136.60	135.14	130.47	
Yakult Italia S.r.l.	Consolidated	96	108.4	Feb. 2007	100.00	EUR	136.60	135.14	130.47	
Europe Total		693	98.4	Marketing Popu	lation: 282,	978 thousa	78 thousand people Population ratio: 0.24 %			
Total	Total 31,273 99		99.2	2 Marketing Population: 2,366,681 thousand people Population ratio: 1.32 %						
(Consolidated subsidiari	Consolidated subsidiaries Total) 22,24									

* Companies are organized in ascending order of business start date by region.

** Exchange Rate : Average Jan. ~ Sep. 2022 : used for Forecasts for the Fiscal year ending Mar. 2023

Average Jan. ~ Jun. 2022 : used for the 2nd quarter result of the Fiscal year ending Mar. 2023

Average Jan. ~ Jun. 2021 : used for the 2nd quarter result of the Fiscal year ended Mar. 2022

(2) Yakult Ladies & Stores by Area and Percentage of Sales by Channel (Excluding Japan)

	(People)	(Stores)					
	Number of			Percentage of Sales by Channel (Volume)			
	Yakult Ladies	delivered to		Yakult Ladies	Stores		
Asia and Oceania	35,619	799,821	Asia and Oceania	44.2%	55.8%		
The Americas	13,970	106,454	The Americas	38.6%	61.4%		
Europe		34,194	Europe		100.0%		
Total	49,589	940,469	Total	42.2%	57.8%		

(As of the end of June 2022)

(From January to June 2022)

(3) Other operating countries

Country	Management company		Country	Management company
Brunei	Yakult (Singapore) Pte. Ltd.		Belize	Yakult S.A. De C.V. (Mexico)
New Zealand	Yakult Australia Pty. Ltd.		Yakult Australia Pty. Ltd. Canada	
United Arab Emirates			Luxembourg	Yakult Belgium N.V./S.A.
Oman			France	
Bahrain	Yakult Middle East FZCO		Switzerland	Voluit Europe D.V.
Qatar			Spain	Yakult Europe B.V.
Kuwait			Denmark	
Uruguay	Yakult S/A Ind. E Com. (Brazil)		Ireland	Yakult UK Ltd.
			Malta	Yakult Italia S.r.l.

(4) Plan for the future

- Currently undergoing feasibility studies
- Middle East and South East Asian countries where we have not made a market entry: Conducting feasibility studies (including field studies) on the possibility of market entry.
- •Other countries where we have not made a market entry: Conducting feasibility studies on the possibility of market entry.

(5) Others

HACCP Accreditation : Hong Kong, Thailand, Korea, Philippines, Australia, Malaysia, Vietnam, India,
Guangzhou, Shanghai, Wuxi, Brazil, Mexico, U.S.A
*HACCP : Hazard Analysis and Critical Control Point
• ISO9001 Accreditation : Hong Kong, Singapore, Australia, India, Guangzhou, Shanghai, Wuxi, Europe, United Kingdom.
*ISO9001 : International Standard for Quality Management Systems
ISO14001 Accreditation : Vietnam, Guangzhou, Europe, United Kingdom, India
●ISO22000 Accreditation : Taiwan, Hong Kong, Singapore, Indonesia, Vietnam, Tianjin, Brazil.
●ISO45001 Accreditation : India.
*ISO45001 : International Standard for Occupational Health and Safety Management Systems
GMP Accreditation : Taiwan, Thailand, Korea, Philippines, Brazil, Mexico.
*GMP:Good Manufacturing Practice
•FSSC22000 Accredidation : Mexico, Europe.
*The FSSC(Food Safety System Certification)22000 is fully recognized by the Global Food Safety Initiative (GFSI) and
is based on existing ISO22000 standards and ISO/TS 22002-1(or ISO/TS 22002-4).
HALAL Accreditation : Taiwan, Thailand, Philippines, Singapore, Indonesia, Malaysia.
●SQF Accreditation : Taiwan, U.S.A
*SQF(Safe Quality Food): International management systems to ensure safety and quality of foods.

OHSAS18001 Accreditation : Vietnam, India.

*OHSAS18001 : An international standard for occupational health and safety management systems.

Non-Consolidated

1. Major Increases (Decreases) in Non-consolidated Balance Sheet

		-		(Millions of yen)
	As of Mar. 31 2022	As of Sep. 30 2022	Increase (Decrease)	Primary reason for change
Total Assets	323,463	326,341	2,878	
Current assets				
Cash and deposits	10,995	7,664	(3,330)	
Accounts receivable - trade	43,864	53,790	9,925	
Inventories	10,671	11,187	515	
Others	13,502	6,625	(6,877)	
Non-current assets				
Property, plant and equipment				
Buildings	28,430	27,874	(555)	
Machinery and equipment	10,769	11,229	460	
Others	28,562	28,977	415	
Intangible assets	2,245	2,182	(63)	
Investments and other assets				
Investment securities	67,325	69,075	1,749	
Shares of subsidiaries and associates	100,819	100,819	_	
Prepaid pension cost	5,735	6,468	732	
Others	539	446	(93)	
Total Liabilities	127,950	136,523	8,573	
Current liabilities				
Accounts payable - trade	15,333	18,312	2,978	
Electronically recorded obligations - operating	8,383	10,143	1,759	
Short-term loans payable	13,010	14,810	1,800	
Accounts payable - other	3,313	2,805	(507)	
Others	21,492	26,103	4,610	
Non-current liabilities				
Long-term loans payable	57,500	55,000	(2,500)	
Others	8,917	9,348	431	
Total Net Assets	195,512	189,818	(5,694)	

2. Major Increases (Decreases) in Non-consolidated Statement of Income

	2Q of FY 2021	2Q of FY 2022	Increase (D	ecrease)		Revised
	(2021.4~9)		Amount	Retio	Primary reason for change	Forecasts* (2022.4~9)
Net sales	78,753	88,123	9,369	11.9		86,000
(Breakdown)						
Dairy products	49,955	59,453	9,497	19.0	Increase in sales of Yakult1000 and Y1000	
Beverages etc.	12,641	12,953	312	2.5		
Cosmetics	3,471	3,354	(116)	(3.4)		
Pharmaceuticals	8,618	7,233	(1,384)	(16.1)	Decrease due to NHI price revision	
Others	4,066	5,127	1,061	26.1		
Cost of sales	42,264	45,285	3,021	7.1		
Gross profit	36,489	42,837	6,348	17.4		
Gross profit margin	46.3	48.6	2.3			
Selling, general and administrative expenses	29,965	28,874	(1,091)	(3.6)		
Selling expenses	11,030	9,457	(1,572)	(14.3)		
General and administrative expenses	18,935	19,416	481	2.5		
Operating profit	6,523	13,963	7,439	114.0		
Operating profit margin	8.3	15.8	7.5			
Non-operating incomes	5,546	7,851	2,304	41.6		
Dividend income	4,645	6,293	1,647			
Others	901	1,558	656			
Non-operating expenses	301	365	63	21.2		
Ordinary profit	11,769	21,450	9,680	82.3		18,500
Ratio of ordinary profit to net sales	14.9	24.3	9.4			
Extraordinary income	1,176	2	(1,173)	(99.8)		
Extraordinary losses	981	59	(921)	(93.9)		
Profit before income taxes	11,964	21,392	9,428	78.8		
Income taxes	1,792	4,062	2,270	126.6		
Profit	10,171	17,329	7,158	70.4		15,000
Ratio of profit to net sales	12.9	19.7	6.8			

* The forecast for 2nd quarter of FY2022 announced on July 29, 2022

Performance Overview 3.

(1) Breakdown of	Statement o	f Income				(Millions	of yen. %)		
	Fisca	al year ended	l March 31, 20	022	Fiscal year ending March 31, 2023				
	Result of				Result of	Year on	Annual	Year on	
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year	
Net sales	78,753	92.5	156,677	93.4	88,123	111.9	175,000	111.7	
Operating profit	6,523	130.3	12,977	169.8	13,963	214.0	22,000	169.5	
Ordinary profit	11,769	99.1	36,448	118.5	21,450	182.3	48,500	133.1	
Profit	10,171	98.8	31,130	114.7	17,329	170.4	39,000	125.3	

(1) Breakdown of Statement of Income

(2) Sales by Product Category

(Millions of yen. %)

(Millions of yen. %)

		Fisca	al year ended	1 March 31, 2	022	Fisca	l year ending	g March 31, 2	023
		Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on
_	1	2nd quarter	year	results	year	2nd quarter	year	forecasts	year
	Dairy products	49,955	108.2	101,801	109.1	59,453	119.0	122,000	119.8
	Beverages etc.	12,641	99.0	23,584	97.7	12,953	102.5	23,500	99.6
s	ub Total	62,597	106.2	125,385	106.7	72,407	115.7	145,500	116.0
С	osmetics	3,471	97.3	6,556	96.3	3,354	96.6	7,000	106.8
P	harmaceuticals	8,618	96.6	16,992	93.8	7,233	83.9	13,000	76.5
0	thers	4,066	29.6	7,743	30.5	5,127	126.1	9,500	122.7
Т	otal	78,753	92.5	156,677	93.4	88,123	111.9	175,000	111.7

(3) Cost to Net sales Ratio

(3) Cost to Net sales Ratio (%)										
	Fisca	al year ended	March 31, 2	022	Fiscal year ending March 31, 2023					
	Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on		
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year		
Cost to Net sales ratio	53.7	(6.3)	53.7	(6.4)	51.4	(2.3)	51.7	(2.0)		

(4) Capital investments, Depreciation

	Fisca	al year ended	I March 31, 2	022	Fiscal year ending March 31, 2023				
	Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on	
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year	
Capital investments	2,890	152.3	5,638	95.6	3,539	122.5	14,000	248.3	
Depreciation	3,796	105.7	7,923	108.1	3,543	93.3	7,400	93.4	

Breakdown of investments

	Fiscal year ended Marcl	h 31, 2022 (Results)	Fiscal year ending March 31, 2023 (Annual forecasts)			
Capital investments	For domestic plants	4.0 billion yen	For domestic plants	11.7 billion yen		

Breakdown of Sales 4.

1) Dairy Products sales (Bottles sold per day) (Thousands of bottles / day. 9									
		year ended	March 31,	2022	Fiscal	year endin	g March 31,	2023	
	Result of 2nd quarter	Year on year	Annual results	Year on year	Result of 2nd quarter	Year on year	Annual forecasts	Year on year	
New Yakult products	4,119	98.5	4,038	98.4	4,326	105.0	4,250	105.3	
(*1) <i>Yakult 400</i> products	2,722	82.3	2,656	82.8	2,471	90.8	2,330	87.7	
(*2) Yakult 1000	1,148	389.7	1,147	268.6	1,808	157.5	2,000	174.4	
Other <i>Yakult</i> products (*3)	96	103.3	216	230.6	^(*4) 501	520.2	^(*5) 620	286.7	
Total for <i>Yakult</i> products	8,085	102.6	8,056	102.9	9,106	112.6	9,200	114.2	
Joie products	563	93.5	563	95.5	555	98.4	540	95.9	
Mil-Mil products	426	93.0	424	91.9	435	102.1	425	100.3	
Sofuhl products	494	111.9	504	113.5	511	103.3	510	101.2	
(*6) Other fermented milk products	95	90.9	91	89.5	90	95.7	85	93.2	
Total for fermented milk	1,578	98.2	1,582	99.1	1,591	100.8	1,560	98.6	
Others ^(*7)	124	91.3	147	95.5	119	95.4	140	95.1	
Total	9,788	101.7	9,786	102.1	10,816	110.5	10,900	111.4	

(1) Dairy Products sales (Bottles sold per day)

(*1) Total of Yakult 400, Yakult 400LT and Yakult 400W.

Yakult 400W

From Jan. 2020 : All of the Kyushu region

From Apr. 2020 : All of the Chugoku & Shikoku regions as well as the prefectures of part of Hyogo, Nara, Wakayama, part of Gifu, Mie, part of Ishikawa & Fukui

From Jun. 2020 : All of the Kinki region as well as the prefectures of Aichi, Gifu, Ishikawa & Toyama

From May 2021 : Tokyo & 6 other prefectures in Kanto (Ibaraki, Tochigi, Gunma, Saitama, Chiba & Kanagawa)

From Aug. 2021 : Launched all over Japan

(*2) Yakult 1000

From Oct. 2019 : Tokyo & 6 other prefectures in Kanto (Ibaraki, Tochigi, Gunma, Saitama, Chiba & Kanagawa) From Aug. 2020 : Hokkaido & Tohoku regions as well as the prefectures of Shizuoka, Yamanashi, Nagano & Niigata From Apr. 2021 : Launched all over Japan

(*3) Total of Yakult Five, Mainichi Nomu Yakult 365, Yakult W and Y1000.

Mainichi Nomu Yakult 365 (Sales were stopped in January 2022).

Yakult W (Sales were stopped in December 2021). Y1000 (Launched in October 2021).

- (*4) The sales bottles of Y1000 is 390 thousands of bottles /day out of 501 thousands of bottles /day.
- (*5) The sales bottles of Y1000 is 500 thousands of bottles /day out of 620 thousands of bottles /day.
- (*6) Total of Aloe Yogurt and Ichinichibun no Tetsu & Yousan Yogurt.
- (*7) Total of BF-1, Pretio, Yakult no Hakko Tonyu and Cup de Yakult.

(2) Beverages sales (Total Bottles sold)

(Thousands of bottles. %)

		Fiscal year ended March 31, 2022			Fiscal year ending March 31, 2023				
		Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on
		2nd quarter	year	results	year	2nd quarter	year	forecasts	year
	Bansoreicha products	7,505	101.1	14,344	99.9	7,161	95.4	13,616	94.9
inks	Toughman products	16,947	99.1	30,189	97.6	17,196	101.5	29,266	96.9
Health drinks	Kurozu Drink product	12,221	88.3	22,758	94.3	12,683	103.8	22,117	97.2
Heal	Soy milk drinks products	15,865	96.1	30,368	94.2	14,652	92.4	28,381	93.5
	Milouge products	10,853	100.9	19,464	101.5	11,741	108.2	18,921	97.2
S	Juices products	17,139	99.7	31,883	98.8	16,164	94.3	30,195	94.7
drinks	Kininaruyasai product	17,319	102.1	32,705	100.7	17,085	98.6	31,589	96.6
Soft e	Coffee Time product	5,743	100.0	10,678	95.5	5,174	90.1	9,862	92.4
	FIRE product	22,050	103.3	43,892	96.5	20,366	92.4	42,842	97.6

(3) Percentage of Sales by Channel (April 1, 2022 to September 30, 2022)

(3) Percentage of Sales by Channel (April 1, 2022 to September 30, 2022) (%)										
	Dairy products (volume-based)		d)						
	Percentage of sales	Year on year	Percentage of sales Year of		Year on year					
Yakult Ladies	49.3	107.5	41.0			96.9				
Stores, Vending machines,	50.7	114.3	59.0	Vending machines	81.2	102.9				
and Others	50.7	114.5	59.0	Stores and Others	18.8	102.9				

Note : Results of Beverages included other company's vending machine operated by Yakult. Note : Actual sales statistics

① Breakdown of sales at Stores, Vending machines, and Others (Dairy products, Beverages)

						(%)	
	For first h	alf ended	For fiscal	year ended	For first half ended		
	Sep. 30	Sep. 30, 2021		Mar. 31, 2022), 2022	
	Percentage	Year on	Percentage	Year on	Percentage	Year on	
	of sales	year	of sales	year	of sales	year	
Supermarkets	50.5	97.1	51.6	105.1	52.0	127.0	
Convenience stores	2.9	89.0	4.3	142.0	7.3	305.7	
Offices	10.4	99.4	9.4	97.9	8.4	99.7	
Medical centers	9.6	100.4	9.2	99.9	7.8	100.4	

(2) The number of delivered vending machine

(2) The number of delivered vending machine (Units							
	As of Mar. 31, 2022	As of Sep. 30, 2022					
The number of vending	41,783	41,325					
machine	(19,848)	(20,791)					

Note : Figures in parentheses are the number of other company's vending machine which Yakult operates.

(4) Brakedown of pharmaceuticals sales

(Millions of yen. %)

	Fiscal	Fiscal year ended March 31, 2022			Fiscal year ending March 31, 2023			
	Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year
Campto	427	99.6	734	74.3	236	55.4	450	61.3
Elplat	4,461	86.6	8,918	91.1	3,764	84.4	7,300	81.8
Gemcitabine	935	83.2	1,789	83.2	855	91.4	1,650	92.2
Other pharmaceuticals	3,095	139.6	6,251	120.4	2,647	85.5	4,190	67.0
Sub Total	8,919	99.9	17,694	97.6	7,504	84.1	13,590	76.8
Deduction amount by "Accounting standard for Revenue recognition"	(301)		(702)		(270)		(590)	
Total	8,618	96.6	16,992	93.8	7,233	83.9	13,000	76.5

5. Breakdown of Selling, General and Administrative Expenses

(Millions of yen. %)

		Fiscal	year ended	March 31, 2	2022	Fiscal	year ending	g March 31,	2023
		Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on
		2nd quarter	year	results	year	2nd quarter	year	forecasts	year
	Advertising expenses	5,728	127.4	11,415	113.3	4,113	71.8	11,227	98.3
	Promotion expenses	1,865	74.3	3,844	78.4	1,682	90.2	4,141	107.7
Sub Total		7,593	108.4	15,260	101.9	5,795	76.3	15,368	100.7
F	reightage expenses	2,801	91.6	5,538	89.1	2,817	100.6	5,837	105.4
Р	ersonnel expenses	11,288	101.0	21,861	100.2	11,709	103.7	22,793	104.3
D	epreciation	1,372	102.4	2,628	97.1	1,121	81.7	2,285	86.9
R	esearch study expenses	803	136.5	1,890	121.6	770	95.9	2,001	105.9
0	thers	6,105	103.7	12,458	103.7	6,660	109.1	14,316	114.9
Т	otal	29,965	103.1	59,638	100.6	28,874	96.4	62,600	105.0

6. Retirement benefit expenses

6. Retirement benefit ez			(Millions o	f yen. %)				
	Fiscal year ended March 31, 2022				Fiscal year ending March 31, 2023			2023
	Result of	Year on	Annual	Year on	Result of	Year on	Annual	Year on
	2nd quarter	year	results	year	2nd quarter	year	forecasts	year
Retirement benefit expenses	916	87.3	1,832	87.3	866	94.6	1,739	94.9

Note: Total of cost of production, general administrative expenses.

7. Head Office Employees

7. Head Office Employees		(People)
	As of Mar. 31, 2022	As of Sep. 30, 2022
Number of full-time employees	2,836	2,859
Medical Representatives	153	149

Note: Both 295 seconded staffs and 171 non-regular employees are included in the number of Mar. 31, 2022.

Both 298 seconded staffs and 173 non-regular employees are included in the number of Sep. 30, 2022.

8. Yakult Sales Company

8. Yakult S	sales Com	ipany	(As of Sep. 30, 2022)
		Consolidated subsidiaries	Comments
Yakult Sales Company	101		The subsidiaries of Yakult Miyagi Chuo Sales Co. Ltd., and Yakult Tokai Co.Ltd., are not included.

Sales Personnel by Department 9.

9. Sales Personnel by Department	(People)	
	As of Mar. 31, 2022	As of Sep. 30, 2022
(1) Yakult Ladies	32,680	32,575
(2) Yakult Beauty Advisors	4,100	3,546

10. Average figure of Yakult Lady

		As of Mar. 31, 2022
Dringing marchandisa a day	Dairy products	145.0 bottles
Bringing merchandise a day	Beverages etc.	16.6 bottles
	Residence	97.5
Number of customers per Yakult lady	Business office	7.6
T akun hady	Others	3.2
Ago and Experience	Age	45.1 years old
Age and Experience	Experience	10 years and 5 months
Activities	Working time	5.4 hours a day
Activities	Working days	20.1 days a month

Reference

1. New Drug Development Pipeline etc.

(1) New Drug Development Pipeline

(1) New Diug Devel	opinent i ipenn	e		(As of September 50, 2022)
Product	Indication	Licensor	Stage	Remarks
① Resminostat Development code : YHI-1001	CTCL ^(*1)	4SC AG	Phase II	Phase II in EU and Japan (CTCL)
	- PTCL ^(*2)		- Phase II	- Phase II in US, EU and Japan (PTCL)
② Duvelisib Development code : YHI-1702	- FL ^(*3)	Secura Bio, Inc.	- Phase II	- Phase II in Japan (FL) ^(*5)
1	- ATL ^(*4)		- Phase II	- Phase II in Japan (ATL) ^(*5)

(*1) CTCL : Cutaneous T cell lymphoma

(*2) PTCL : Peripheral T-cell lymphoma

(*3) FL : Follicular lymphoma

(*4) ATL : Adult T-cell leukemia/lymphoma

(*5) The procedures for discontinuing Phase II studies for Duvelisib in patients with FL and ATL are progressing as of November 11th, 2022.

(2) National health insurance reimbursement information

				(Yen. %)
	Since April 2022	As of end of March 2022	Revision rate	Reference
<i>Campto</i> Infusion solution (40mg/Vial)	2,036	2,427	(16.1)	[Major regimens combined with Elplat, Campto,and Calcium levofolinate] 1. Advanced/recurrent colorectal cancer
<i>Campto</i> Infusion solution (100mg/Vial)	4,594	5,469	(16.0)	 FOLFOX regimen (Elplat + Calcium levofolinate + Fluorouracil) CAPOX regimen (Elplat + Capecitabine) FOLFOXIRI regimen (Elplat, Campto, Calcium levofolinate,
<i>Elplat</i> IV infusion solution 50mg	16,012	18,655	(14.2)	and Fluorouracil) 2. Post operative treatment (adjuvant) for colon cancer - FOLFOX regimen (Elplat + Calcium levofolinate +
<i>Elplat</i> IV infusion solution 100mg	29,086	33,890	(14.2)	Fluorouracil) - CAPOX regimen (Elplat + Capecitabine) 3. Gastric cancer (Advanced / recurrent, adjuvant)
<i>Elplat</i> IV infusion solution 200mg	52,076	61,126	(14.8)	 SOX regimen (Elplat + Tegafur / Gimeracil / Oteracil potassium) CAPOX regimen (Elplat + Capecitabine)
Calcium <i>levofolinate</i> for IV infusion 25mg	523	580	(9.8)	 Pancreatic cancer FOLFIRINOX regimen (Elplat, Campto, Calcium levofolinate, and Fluorouracil)
Calcium <i>levofolinate</i> for IV infusion 100mg	1,774	1,977	(10.3)	

(Yen %)

(As of September 30, 2022)

2. Situation of Yakult Group (Production Facilities)

< Yakult Honsha Plants >

(As of September 30, 2022)

	ISO	ISO 22000	production item
Fukushima Plant	0	0	Concentrated New Yakult, Concentrated New Yakult Calorie Half, Concentrated Yakult 1000, Mil-Mil, Mil-Mil S, Sofuhl, Cup de Yakult
Ibaraki Plant	0	0	Concentrated <i>New Yakult Calorie Half</i> , Concentrated <i>Yakult 400LT</i> , Concentrated <i>Yakult 1000</i> , Concentrated <i>Yakult Five</i> , <i>Y 1000</i>
Fuji Susono Plant	0	0	Concentrated Yakult 400LT, Joie, Aloe Yogurt, Ichinichibun no Tetsu & Yousan Yogurt, Yakult 1000, Sofuhl (Limited-time-only product)
Hyogo Miki Plant	0	0	Concentrated New Yakult, Concentrated Yakult 400, Concentrated Yakult 400W, Concentrated Yakult 1000, Sofuhl, Mil-Mil, Pretio, BF-1
Saga Plant	0	0	Concentrated <i>New Yakult</i> , Concentrated <i>New Yakult Calorie Half</i> , Concentrated <i>Yakult 400LT</i> , Concentrated <i>Yakult 1000</i> , <i>Mil-Mil S</i> , <i>Y 1000</i>
Shonan Cosmetics Plant	0		Cosmetics
Fuji Susono Pharmaceutical Plant	0	_	Prescription drugs, Active pharmaceutical ingredient for prescription drugs, Active pharmaceutical ingredient for quasi-pharmaceutical drugs

< Subsidiary Plants >

	ISO 14001	ISO 22000	production item
Yakult Iwate Plant Co.,Ltd.	0	0	New Yakult , New Yakult Calorie Half , Yakult 400LT , Yakult Five , Yakult 1000
Yakult Chiba Plant Co.,Ltd.	0	0	New Yakult Calorie Half, Yakult 1000
Yakult Aichi Plant Co.,Ltd.	0	0	New Yakult , Yakult 400LT
Yakult Okayama Wake Plant Co.,Ltd.	0	0	New Yakult , Yakult 400 , Yakult 400W , Yakult 1000
Yakult Fukuoka Plant Co.,Ltd.	0	0	New Yakult , New Yakult Calorie Half, Yakult 400LT, Yakult 1000

International Organization for Standardization (ISO)

ISO 14001-- The International Standard for Environmental Management Systems

ISO 22000-- The International Standard for Food Safety Management Systems

Overseas Dairy Products sales amount (Preliminary figure) 3.

[Performance from January to September 2022.]

Hong Kong Yakult Co., Ltd.Consolidated36181.6Yakult (Thailand) Co., Ltd.Equity method2,286115.2Korea Yakult (hy Co., Ltd.)Equity method2,47991.1YaYakult Philippines, Inc.Equity method3,777104.5Yakult (Singapore) Pte. Ltd.Consolidated24894.2YakultPT. Yakult Indonesia PersadaConsolidated7,364101.7Yakult Australia Pty. Ltd.Consolidated314109.0	Main ProductsYakult, Yakult 300, Yakult 300Light, JoieYakult, Yalult LT, JoieYakult, Yakult LightKult Light, Yakult Premium LightYakult, Yakult Premium LightYakult, Yakult Light	Base of production O O O O O O O O O O O O O	Base of production 1 1 2 3 1 2 1 2 1 1
Yakult Taiwan Co., Ltd.Equity method67695.4Yakult, NewHong Kong Yakult Co., Ltd.Consolidated36181.6Yakult (Thailand) Co., Ltd. (*2)Equity method2,286115.2Korea Yakult (hy Co., Ltd.)Equity method2,47991.1Yakult Philippines, Inc.Equity method3,777104.5Yakult (Singapore) Pte. Ltd.Consolidated24894.2YakultPT. Yakult Indonesia PersadaConsolidated7,364101.7Yakult Australia Pty. Ltd.Consolidated314109.0	Yakult, Yalult LT, Joie Yakult, Yakult Light kult Light, Yakult Premium Light Yakult, Yakult Light Yakult Light, Yakult Ace Light Yakult Yakult, Yakult Light	0 0 0 0 0 0 0 0 0	1 2 3 1 1 2
Hong Kong Yakult Co., Ltd.Consolidated36181.6Yakult (Thailand) Co., Ltd. (*2)Equity method2,286115.2Korea Yakult (hy Co., Ltd.)Equity method2,47991.1YaYakult Philippines, Inc.Equity method3,777104.5744Yakult (Singapore) Pte. Ltd.Consolidated24894.2YakPT. Yakult Indonesia PersadaConsolidated7,364101.7744Yakult Australia Pty. Ltd.Consolidated314109.0744	Yakult, Yalult LT, Joie Yakult, Yakult Light kult Light, Yakult Premium Light Yakult, Yakult Light Yakult Light, Yakult Ace Light Yakult Yakult, Yakult Light	0 0 0 0 0 0	1 2 3 1 1 2
Yakult (Thailand) Co., Ltd. (*2)Equity method2,286115.2Korea Yakult (hy Co., Ltd.)Equity method2,47991.1YaYakult Philippines, Inc.Equity method3,777104.5Yakult (Singapore) Pte. Ltd.Consolidated24894.2YakuPT. Yakult Indonesia PersadaConsolidated7,364101.7Yakult Australia Pty. Ltd.Consolidated314109.0	Yakult, Yakult Light kult Light , Yakult Premium Light Yakult, Yakult Light cult, Yakult Light, Yakult Ace Light Yakult Yakult, Yakult Light Yakult, Yakult Light	0 0 0 0 0	2 3 1 1 2
Korea Yakult (hy Co., Ltd.)Equity method2,47991.1YakultYakult Philippines, Inc.Equity method3,777104.5Yakult (Singapore) Pte. Ltd.Consolidated24894.2YakultPT. Yakult Indonesia PersadaConsolidated7,364101.7Yakult Australia Pty. Ltd.Consolidated314109.0	kult Light , Yakult Premium Light Yakult, Yakult Light cult, Yakult Light, Yakult Ace Light Yakult Yakult Yakult, Yakult Light Yakult, Yakult Light	0 0 0 0	3 1 1 2
Yakult Philippines, Inc.Equity method3,777104.5Yakult (Singapore) Pte. Ltd.Consolidated24894.2YakultPT. Yakult Indonesia PersadaConsolidated7,364101.7Yakult Australia Pty. Ltd.Consolidated314109.0	Yakult, Yakult Light ult, Yakult Light, Yakult Ace Light Yakult Yakult, Yakult Light Yakult, Yakult Light	0 0 0 0	1 1 2
Yakult (Singapore) Pte. Ltd.Consolidated24894.2YakultPT. Yakult Indonesia PersadaConsolidated7,364101.7Yakult Australia Pty. Ltd.Consolidated314109.0	ult, Yakult Light, Yakult Ace Light Yakult Yakult, Yakult Light Yakult, Yakult Light	0 0 0	1 2
PT. Yakult Indonesia Persada Consolidated 7,364 101.7 Yakult Australia Pty. Ltd. Consolidated 314 109.0	Yakult Yakult, Yakult Light Yakult, Yakult Light	0	2
Yakult Australia Pty. Ltd. Consolidated 314 109.0	Yakult, Yakult Light Yakult, Yakult Light	0	
	Yakult, Yakult Light		1
	~	0	
Guangzhou Yakult Co., Ltd. Consolidated 2,760 91.0	Yakult Ace, Yakult Ace Light		3
Yakult (Malaysia) Sdn. Bhd.Consolidated418125.9		0	1
Shanghai Yakult Co., Ltd. Consolidated 394 84.6	Yakult, Yakult Light	0	1
Beijing Yakult Co., Ltd. Consolidated 341 89.9	Yakult, Yakult Light		
Yakult (China) Corporation ^(*3) Consolidated 3,298 87.9	Yakult, Yakult Light		2
Yakult Vietnam Co., Ltd. Consolidated 904 116.5	Yakult		1
Yakult Danone India Pvt. Ltd. Consolidated 242 105.1	Yakult, Yakult Light		1
Yakult Middle East FZCO Consolidated 17 81.8	Yakult, Yakult Light, Yakult Gold		
Yakult Myanmar Co., Ltd. ^(*5) Consolidated — —	Yakult	0	1
Asia and Oceania Total 25,878 98.6 Marketing F	Population: 1,544,469thousand people Popul	ation ratio: 1.68%	%
(Consolidated subsidiaries company Total) 16,661 96.7			
Yakult S/A Ind. E Com. (Brazil)Consolidated1,417100.8Yak	.8 Yakult, Yakult 40, Yakult 40LT, Sofyl		1
Yakult S.A. De C.V. (Mexico) Consolidated 3,746 108.4 Yakult, Yak	Yakult, Yakult40LT, Soful LT, Soful LT(Drink type)		2
Yakult U.S.A. Inc.Consolidated632115.5	Yakult, Yakult Light		1
The Americas Total5,795107.2Marketing F	Marketing Population: 539,235 thousand people Population ratio: 1.07)
Yakult Nederland B.V.Consolidated17494.9	9 Yakult, Yakult Light, Yakult Plus Yakult Europe		
Yakult Belgium N.V./S.A.Consolidated5697.5	Yakult, Yakult Light, Yakult Plus		
Yakult Europe B.V. (*6) Consolidated 26 94.5	Yakult, Yakult Plus		1
Yakult UK Ltd. Consolidated 232 97.6	Yakult, Yakult Light		
Yakult Deutschland GmbH Consolidated 76 98.7	Yakult, Yakult Light, Yakult Plus Yaku		
Yakult Oesterreich GmbH Consolidated 10 90.8	Yakult, Yakult Plus Yakult Europe		
Yakult Italia S.r.l.Consolidated94106.5	5 Yakult, Yakult Light, Yakult Plus Yakult Europe		
Europe Total66897.9Marketing F	Marketing Population: 282,978 thousand people Population ratio: 0.24 %		
Total 32,341 100.0 Marketing Popul	ation: 2,366,681 thousand people Population ratio: 1.37 %	Factory Total	27
(Consolidated subsidiaries company Total) 23,124 99.2			

< Accounting period: From January to December >

(*1) Companies are organized in ascending order of business start date by region.

(*2) Yakult (Thailand) Co., Ltd. : Accounting date : 31st May.

(*3) Sales Base of Yakult (China) Corporation : Nanjing city, Tianjin city, Suzhou city, Hangzhou city, Qingdao city, Ningbo city, Jinan city, Yantai city, Wuhan city, Wenzhou city, Shenyang city, Dalian city, Fuzhou city, Xiamen city, Hefei city, Changsha city, Xi'an city, Nanchang city, Changchun city, Shijiazhuang city, Chengdu city, Chongqing city, Zhengzhou city, Taiyuan city, Harbin city, Hohhot city, Jinhua city, Huaian city, Kunming city, Nanning city, Jiaxing city, Wuxi city, Guiyang city, Lanzhou city, Nantong city, Shaoxing city, Hengyang citiy, Wuhu city. (excluding Guangdong and Hainan, Shanghai city, Beijing city)

(*4) Yakult Danone India Pvt. Ltd. : Accounting date : 31st March.

(*5) Yakult Myanmar Co., Ltd. : Accounting date : 31st March.

(*6) Sales Area of Yakult Europe B.V. : France, Switzerland, Denmark, Spain

4. Environmental Response

(1) Greenhouse Gas (GHG) emissions

(1) CO₂ emissions (Scope 1 +Scope 2)

	Fiscal 2018	Fiscal 2021	Compared to fiscal 2018 levels
Scope 1 CO ₂ emissions (t-CO ₂)	39,229	41,131	104.9 %
Scope 2 CO ₂ emissions (t-CO ₂)	48,890	42,450	86.8 %

Note: Targets on Environmental Actions (2021-2024)

By the end of fiscal 2024, reduce GHG emissions (in Japan, scopes 1 and 2) by 10% compared to fiscal 2018 levels.

(2) Scope 3 emissions (Only applicable categories)

CO2 emissions in Fiscal 2021	324,452 t	
------------------------------	-----------	--

Note1: Yakult Honsha (including logistics) and five bottling companies calculated in scope

Note2: Our applicable categories in the GHG protocol (one of the GHG Accounting Standards) are 1"Purchased goods and services", 2"Capital goods", 3"Fuel- and energy-related activities not included in scopes 1 or 2", 5"Waste generated in operations", 6"Business travel", 7"Employee commuting", 9"Downstream transportation and distribution", 12"End-of-life treatment of sold products" and 13"Downstream leased assets".

Note3: Scope definitions

Scope 1: Direct emissions from fuel used for company's own business activities

Scope 2: Indirect emissions from generation of electricity, steam and heat purchased from outside company

Scope 3: Emissions from across supply chain related to company's business activities

(2) The amount of plastic used in containers and packaging (in Japan)

	Fiscal 2018	Fiscal 2021	Compared to fiscal 2018 levels
The amount of plastic used (t)	14,782	15,637	105.8 %

Note: Targets on Environmental Actions (2021-2024)

By the end of fiscal 2024, reduce plastic containers and packaging (in Japan) by 5% compared to fiscal 2018 levels, or make them recyclable.

(3) Water used at Yakult Honsha plants and bottling companies and use per production unit

	Fiscal 2018	Fiscal 2021	Compared to fiscal 2018 levels
Yakult Honsha plants water use ($1,000\text{m}^3$)	1,237	1,253	101.3 %
Bottling companies water use ($1,000 \mathrm{m}^3$)	449	439	97.8 %
Water use per production unit (m^3 / kl)	5.83	5.69	97.6 %

Note1: Water use per production unit is calculated using data from bottling companies and five Yakult Honsha plants,

excluding those plants producing cosmetics and pharmaceuticals.

Note2: Targets on Environmental Actions (2021-2024)

By the end of fiscal 2024, reduce water consumption (at dairy product plants in Japan, per production unit) by 3% compared to fiscal 2018 levels.

(4) Response for Task Force on Climate-Related Financial Disclosures (TCFD)

We expressed our support for TCFD on August 17, 2022. Currently, based on our understanding of the actual situation, we have proceeded with the measures recommended by TCFD for disclosure.

(5) The evaluations by ESG evaluation institutions

	Index Name	Evaluation
1	FTSE Blossom Japan Index	3.7
2	MSCI Japan ESG Select Leaders Index	BBB
3	S&P/JPX Carbon Efficient Index	9

The evaluations by major ESG evaluation institutions are as follows.

CAUTIONARY STATEMENT

Statements contained in these materials with respect to Yakult's plans, forecasts and other statements that are not historical facts but forward - looking statements that involve risks and uncertainties that could result in actual results differing substantially from expectations.

The information contained in these materials is not intended as a solicitation for investment.Furthermore, Yakult does not guarantee the accuracy of the contents of these materials.Yakult and the provider of these materials disclaim any responsibility for any loss or damage that should arise from the use of this information.